Asenapine is a second generation antipsychotic drug with sub lingual administration whose efficacy has been proven between 10 and 20 mg per day in the treatment of manic phases and mixed states related with bipolar disorder. The aim of this study is to evaluate with an open retrospective trial the efficiency and tolerability of a low dose of asenapine (5 mg per day) in the treatment of patients diagnosed with bipolar disorder II. Preliminary data obtained in this study, even if based on a small sample in a naturalistic context, provide supportive evidence that the treatment with asenapine 5 mg per day improves the outcome in patients with bipolar disorder type II.
Asenapine in the treatment of bipolar disorder type II: a retrospective study / C. Di Genova, C. Galimberti, C. Viganò, R. Bassetti, R. Truzoli, M. Bosi, G. Ba. ((Intervento presentato al 5. convegno International forum : Innovation in psychiatry : Major psychoses: old concepts or new diagnostic, clinical and therapeutic challenges? tenutosi a Milano nel 2013.
Asenapine in the treatment of bipolar disorder type II: a retrospective study
C. Di GenovaPrimo
;C. GalimbertiSecondo
;C. Viganò;R. Bassetti;R. Truzoli;G. BaUltimo
2013
Abstract
Asenapine is a second generation antipsychotic drug with sub lingual administration whose efficacy has been proven between 10 and 20 mg per day in the treatment of manic phases and mixed states related with bipolar disorder. The aim of this study is to evaluate with an open retrospective trial the efficiency and tolerability of a low dose of asenapine (5 mg per day) in the treatment of patients diagnosed with bipolar disorder II. Preliminary data obtained in this study, even if based on a small sample in a naturalistic context, provide supportive evidence that the treatment with asenapine 5 mg per day improves the outcome in patients with bipolar disorder type II.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
